LN-229 Xenograft Model Service for Glioblastoma

The LN-229 xenograft model offers a robust and clinically relevant platform for preclinical glioblastoma research, recapitulating the infiltrative growth patterns and molecular heterogeneity characteristic of human disease. Alfa Cytology leverages this well-established model to deliver comprehensive, GLP-compliant preclinical services---from tumor cell implantation and longitudinal monitoring to advanced histopathological and molecular endpoint analysis---enabling pharmaceutical and biotech partners to accelerate therapeutic development with confidence.

Overview of LN-229 Xenograft Model for Glioblastoma

The LN-229 cell line, originally isolated from a patient with glioblastoma multiforme (GBM), has emerged as a cornerstone for preclinical brain tumor research due to its distinct biological properties. Unlike the U87MG line, which forms compact, well-demarcated tumors, LN-229 cells exhibit diffuse, infiltrative margins that closely mirror the invasive behavior observed in human GBM. This cell line carries key molecular alterations including mutations in TP53, homozygous deletion of p16 and p14ARF, and wild-type PTEN status, making it particularly valuable for studying tumor-microenvironment interactions and evaluating therapeutic agents targeting these pathways. In orthotopic xenograft settings, LN-229 tumors demonstrate slower growth kinetics compared to U87, typically reaching peak volume around 8 weeks, and show pronounced dispersal along cerebral blood vessels---a hallmark of clinical glioblastoma progression.

The LN-229 xenograft model has been extensively utilized to investigate the CXCR4-STAT3 axis, autocrine VEGF signaling, and the role of tumor-infiltrating microglia and macrophages in promoting malignant progression. Cryo-imaging studies have further demonstrated that LN-229 tumors exhibit significant dispersal with mean dissemination distances of approximately 63 um, predominantly occurring along existing vasculature. These characteristics make the LN-229 model an indispensable tool for assessing anti-invasive therapies, studying blood-brain barrier penetration, and evaluating immunotherapeutic strategies in a physiologically relevant context.

Figure 1. LN-229 cells were treated with increasing concentrations of HB007 for 48 hours and analyzed by cell viability assay for growth inhibition. (Dougherty, C, et al., 2023)

Cell Line Information: LN-229

The following table summarizes the essential characteristics and molecular profile of the LN-229 human glioblastoma cell line, providing researchers with critical reference data for experimental design and data interpretation.

Our Services

Alfa Cytology provides end-to-end LN-229 xenograft model services tailored to your preclinical research objectives. Our integrated platform encompasses orthotopic and subcutaneous implantation, longitudinal tumor monitoring via bioluminescence imaging and MRI, comprehensive histopathological analysis, and molecular endpoint characterization---including immunohistochemistry, flow cytometry, and transcriptomic profiling. With rigorous quality control, IACUC-approved protocols, and dedicated project management, we ensure reproducible, publication-ready data that accelerates your therapeutic pipeline from candidate selection to IND-enabling studies.

Workflow of LN-229 Xenograft Model Construction

Alfa Cytology follows a standardized, IACUC-approved workflow to construct reliable LN-229 xenograft models, ensuring reproducible tumor growth and high-quality data output. The process spans from cell preparation and quality verification to surgical implantation, post-operative monitoring, and endpoint analysis. Each step is executed under strict GLP-compliant conditions with comprehensive documentation to support regulatory submissions and peer-reviewed publications.

1. Cell Line Authentication and Quality Control: LN-229 cells are authenticated via STR profiling and confirmed mycoplasma-free before expansion. Cells are maintained in DMEM with 10% FBS under standard culture conditions, and early-passage stocks (P3--P8) are used to minimize genetic drift and ensure consistent tumorigenicity across batches.
2. Reporter Cell Preparation (Optional): For longitudinal monitoring, LN-229 cells are stably transduced with luciferase or GFP reporters using lentiviral vectors. Transduced populations are sorted by FACS to achieve >95% purity, and expression stability is verified over multiple passages prior to implantation.
3. Animal Selection and Acclimation: Immunodeficient mice (BALB/c nude, NOD/SCID, or NSG; 6--8 weeks old) are acclimated for at least 5 days under pathogen-free conditions. Animals are randomized by body weight and assigned to treatment groups using stratified randomization to minimize baseline variability.
4. Tumor Cell Preparation for Implantation: LN-229 cells are harvested at 70--80% confluence using trypsin-EDTA, washed twice in sterile PBS, and resuspended at the desired concentration---typically 1x10^5 cells/3 uL for orthotopic injection or 2x10^6 cells/100 uL for subcutaneous implantation. Cell viability is confirmed by trypan blue exclusion (>95% viability required).
5. Surgical Implantation -- Orthotopic Model: For orthotopic models, mice are anesthetized with isoflurane and secured in a stereotaxic frame. A midline scalp incision is made, and a burr hole is drilled at coordinates AP +0.5 mm, ML -1.8 mm relative to bregma. LN-229 cells (1x10^5 in 3 uL PBS) are injected slowly into the striatum (DV -3.0 mm) using a Hamilton syringe over 3--5 minutes, followed by a 5-minute dwell time to prevent backflow. The burr hole is sealed with bone wax, and the scalp is sutured.
6. Subcutaneous Implantation (Alternative): For subcutaneous models, mice are briefly anesthetized, and 2x10^6 LN-229 cells in 100 uL PBS (mixed 1:1 with Matrigel for enhanced engraftment) are injected into the right flank using a 25-gauge needle. Tumor palpation begins 7--10 days post-implantation, with caliper measurements recorded every 3--4 days.
7. Post-Operative Monitoring and Care: Animals receive buprenorphine (0.05--0.1 mg/kg) for post-operative analgesia and are monitored daily for neurological symptoms, body weight, and general health. Neurological scoring (e.g., limb clasping, circling, hunched posture) is recorded to determine humane endpoints.
8. Longitudinal Tumor Monitoring: For luciferase-expressing models, tumor growth is monitored weekly via IVIS bioluminescence imaging after intraperitoneal D-luciferin injection. For non-reporter models, MRI (T2-weighted) is performed at 2, 4, 6, and 8 weeks post-implantation to quantify tumor volume and assess infiltrative spread.
9. Endpoint Analysis and Tissue Collection: At the predetermined endpoint (tumor volume ~2,000 mm^3 for subcutaneous; onset of neurological symptoms for orthotopic), animals are euthanized by CO2 inhalation. Brains and/or tumors are harvested, fixed in 4% paraformaldehyde, and processed for paraffin embedding. Serial sections are prepared for H&E staining, IHC (e.g., Ki-67, CD31, GFAP, Iba-1), and immunofluorescence.
10. Data Compilation and Reporting: All raw data---including tumor growth curves, imaging files, histology images, and IHC quantification---are compiled into a comprehensive study report with statistical analysis. Data are delivered in publication-ready formats with full traceability for regulatory and manuscript submission purposes.

Figure 2. LN-229 xenograft model construction workflow.

Case Study-LN-229 Xenograft Model Development

In a recent preclinical engagement, Alfa Cytology developed an orthotopic LN-229 xenograft model to evaluate the efficacy of a novel small-molecule inhibitor targeting the CXCR4-STAT3 signaling axis. The study demonstrated robust tumor engraftment with 100% take rate, progressive infiltrative growth along cerebral vasculature over an 8-week observation period, and dose-dependent reduction in tumor dispersal following therapeutic intervention. Comprehensive endpoint analysis---including MRI volumetrics, H&E histopathology, and multiplex IHC for Ki-67, CD31, and Iba-1---provided mechanistic insights into both anti-proliferative and anti-angiogenic effects. Detailed quantitative data, including tumor growth kinetics, survival curves, and biomarker expression profiles, are available upon request under confidentiality agreements. Please contact our scientific team to discuss how this validated model can be adapted for your specific therapeutic program.

Why Choose Alfa Cytology?

Alfa Cytology distinguishes itself as a premier preclinical CRO through rigorous scientific execution, operational transparency, and unwavering commitment to data integrity. Our LN-229 xenograft service is built upon validated protocols, experienced neuro-oncology specialists, and a fully integrated infrastructure designed to advance your glioblastoma therapeutic pipeline efficiently and reliably.

• Validated, publication-ready LN-229 xenograft models with documented tumorigenicity, growth kinetics, and molecular fidelity.
• Flexible orthotopic and subcutaneous implantation options with reporter cell integration (luciferase, GFP) for real-time, non-invasive tumor monitoring.
• Comprehensive endpoint portfolio including MRI, bioluminescence imaging, histopathology, IHC, flow cytometry, and transcriptomic analysis.
• GLP-compliant workflows with full IACUC oversight, AAALAC-accredited facilities, and complete regulatory documentation for IND submissions.
• Dedicated project management with transparent milestone tracking, weekly progress updates, and rapid turnaround on study reports.
• Customizable study designs accommodating combination therapies, radiation protocols, immunotherapy co-administration, and pharmacokinetic sampling.
• Competitive pricing with no hidden fees, flexible milestone-based billing, and dedicated scientific consultation included in every project.

Contact Us

Ready to accelerate your glioblastoma therapeutic program with a validated LN-229 xenograft model? Reach out to Alfa Cytology today to discuss your project requirements, receive a customized study proposal, and partner with a CRO committed to scientific excellence and regulatory precision. Our team of neuro-oncology specialists is standing by to transform your research objectives into actionable, data-driven outcomes---contact us now to get started. Please reach out to us today via our inquiry form or email to learn more about our LN-229 Xenograft Model services.

For research use only. Not intended for any clinical use.